

Table of Contents

Preface.....	ix
DRI Mission, Diversity Statements.....	x
DRI Officers.....	xi
DRI Directors.....	xi
Chapter 1	
Introduction to the FDA.....	1
By Matthew E. Brown, Brandee J. Kowalzyk, and Mark R. Nash	
Federal Food, Drug and Cosmetic Act.....	1
FDA Departments and Organization.....	4
Center for Devices and Radiological Health (CDRH).....	6
Center for Drug Evaluation and Research (CDER).....	7
FDA's Issuance of Guidances.....	8
FDA's Use of Advisory Committees.....	10
FDA's Handling of Companies' Confidential Information (FOIA).....	14
FDA Employee Testimony.....	17
Meeting Requests to the FDA.....	19
Drug Manufacturers.....	19
Medical Device Manufacturers.....	22
Chapter 2	
Drug Approvals, Medical Device Approvals, and Clinical Trials and Registries.....	25
Section 1: Drug Approvals.....	25
By Tariq M. Naem, Andrea Glinka Przybysz, and Brenda A. Sweet	
Prescription Drugs.....	25
Investigational New Drug Applications.....	27
New Drug Applications.....	28
Abbreviated New Drug Applications.....	35
OTC Drugs.....	36
Approval of OTC Medications as New Drugs.....	37
Introduction of OTC Medications in Accordance with the Monograph Process.....	39

Introduction of OTC Medications Pursuant to a Time and Extent Application.....	43
Biologics.....	44
Regulation by CDER and CBER.....	45
Submission of Biologics License Application.....	46
Agency Response.....	48
Complete Response Letter.....	48
Denial.....	49
Market Exclusivity and Biosimilars.....	49
Withdrawal of Licensure (Voluntary or Involuntary).....	51
Section 2: Medical Device Approvals.....	53
By Denise Bense	
The FDA's Medical Device Approval Process.....	53
Three Medical Device Classes.....	54
Preamendment Medical Devices.....	55
Postamendment Medical Devices.....	55
510(k) Clearance Process.....	56
Premarket Approval Application (PMA) Process.....	59
Significance of a PMA Approval in Litigation.....	62
Section 3: Clinical Trials and Clinical Trial Registries.....	65
By Gail Javitt and Ryan Kaat	
Informed Consent.....	66
Data Integrity.....	71
Conflicts of Interest.....	74
Clinical Trial Registries (ClinicalTrials.gov).....	75
Chapter 3	
Labeling.....	78
By Glenn S. Kerner and Nilda M. Isidro	
Content.....	79
Drug Labeling.....	79
Medical Devices.....	86
Label Approval.....	90
Drug Labeling Approval.....	90
Medical Device Approval.....	97

Monographs.....	100
OTC Drug Review Process.....	100
FDA Examination of OTC Drug Review Process	102
Case Law Involving Monographs.....	104
Medication Guides	105
Regulation of Medication Guides.....	106
FDA Guidance on Medication Guides.....	108
Case Law Involving Medication Guides	112
Off-Label Use	115
FDA’s Position on Off-Label Use	115
Draft Guidance Regarding Distribution of Off-Label Use Information	116
Case Law Involving Off-Label Use.....	123
 Chapter 4	
Advertising and Promotions.....	126
By J. Dominic Campodonico, Andrew W. Cary, and Gene W. Kim	
Regulation of Labeling and Advertising of Drugs and Medical Devices.....	127
Prescription Drug and Medical Device Labeling, Advertising and Promotion	127
Drug and Medical Device Advertising and Promotion	128
“Misbranding”—Prohibited Acts and Violations of the FDCA	129
Prohibited Acts and Violations of the Federal Trade Commission Act (the FTCA).....	133
“Intended Use” and “Off-Label” Promotion.....	134
Defenses to Claims Alleging Off-Label Marketing	139
Direct-to-Consumer Advertising.....	140
Internet and Social Media.....	141
 Chapter 5	
Manufacturing Regulations	145
By Rebecca Jones McKnight, Rachael Hunt, and Andrew J. Hoffman II	
FDA Enforcement Authority.....	145
Adulteration Due to Non-Compliance with GMPs.....	145
The Substance of GMPs for Finished Drugs and Devices	149

Inspections and Audits.....	158
Authority and Reasons Prompting FDA Inspections	158
The Inspector’s Arrival	159
483 Observations and Warning Letters	168
Product Recalls, Corrections and Withdrawals.....	175
Defining a “Recall”	175
Carrying out a Recall	178
Heightened Enforcement, Including Criminal Actions.....	180
Seizures	181
Injunctions	181
Consent Decrees and Disgorgement.....	182
Civil Money Penalties for Device-Related Violations.....	182
Criminal Liability.....	183
False Claims Act	184

Chapter 6

Post-Approval Commitments.....	186
--------------------------------	-----

By Jennifer A. Foster and Shelby K. Feuerbach

Adverse Event Reporting and Post-Marketing Surveillance.....	187
Prescription Drugs and Pharmaceutical Products	188
Medical Devices	192
Annual Reports.....	197
Prescription Drugs	197
Medical Devices	201
Dear Doctor Letters (Dear Health Care Provider letters)	203
Prescription Drugs and Pharmaceutical Products	203
Medical Devices	210
Safety Alerts.....	212

Glossary of Acronyms and Terms	215
--------------------------------------	-----

Contributors	224
Editors.....	224
Contributing Authors.....	225